Total Payments
$3,340
2024 Payments
$637.22
Companies
34
Transactions
139
Medicare Patients
2,847
Medicare Billing
$314,491
Payment Breakdown by Category
Food & Beverage$2,081 (62.3%)
Other$1,139 (34.1%)
Education$120.04 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,081 | 135 | 62.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,139 | 1 | 34.1% |
| Education | $120.04 | 3 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $1,246 | 7 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $394.97 | 28 | $0 (2024) |
| PFIZER INC. | $339.73 | 26 | $0 (2024) |
| Janssen Biotech, Inc. | $295.11 | 16 | $0 (2024) |
| Astellas Pharma US Inc | $128.93 | 7 | $0 (2024) |
| Foundation Medicine, Inc. | $120.27 | 2 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $72.92 | 4 | $0 (2024) |
| TAIHO ONCOLOGY, INC. | $70.50 | 5 | $0 (2024) |
| Mirati Therapeutics, Inc. | $66.59 | 4 | $0 (2024) |
| Eisai Inc. | $63.72 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $637.22 | 38 | PFIZER INC. ($162.57) |
| 2023 | $441.37 | 27 | Novartis Pharmaceuticals Corporation ($147.74) |
| 2022 | $336.54 | 23 | Novartis Pharmaceuticals Corporation ($206.23) |
| 2021 | $626.83 | 44 | PFIZER INC. ($120.43) |
| 2020 | $159.33 | 6 | Janssen Biotech, Inc. ($76.95) |
| 2018 | $1,139 | 1 | Incyte Corporation ($1,139) |
All Payment Transactions
139 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $8.48 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $6.19 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $35.33 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.45 | General |
| Category: Oncology | ||||||
| 10/23/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $16.78 | General |
| Category: Hematology/Oncology | ||||||
| 10/02/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $34.03 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/13/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: BioOncology | ||||||
| 08/16/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: Oncology | ||||||
| 08/13/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $10.92 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: Oncology | ||||||
| 07/24/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Oncology | ||||||
| 07/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 06/26/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $21.75 | General |
| Category: Oncology | ||||||
| 06/07/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: Oncology | ||||||
| 06/06/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $12.24 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $13.54 | General |
| Category: Hematology/Oncology | ||||||
| 05/07/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $12.04 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: ONCOLOGY | ||||||
| 04/24/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 961 | 25,602 | $459,489 | $143,122 |
| 2022 | 17 | 728 | 4,302 | $282,422 | $80,486 |
| 2021 | 18 | 686 | 1,724 | $128,824 | $51,855 |
| 2020 | 12 | 472 | 791 | $129,164 | $39,028 |
Total Patients
2,847
Total Services
32,419
Medicare Billing
$314,491
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 2 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 12 | 35 | $140.00 | $29.54 | 21.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 72 | 208 | $33,696 | $20,796 | 61.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 33 | 172 | $61,060 | $16,352 | 26.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 71 | 159 | $18,285 | $9,136 | 50.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 62 | 64 | $14,400 | $6,694 | 46.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 30 | 263 | $23,670 | $6,229 | 26.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 45 | 45 | $11,925 | $5,853 | 49.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 49 | 85 | $8,840 | $5,766 | 65.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 103 | 356 | $14,596 | $2,724 | 18.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 13 | 78 | $6,240 | $1,801 | 28.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 20 | 34 | $5,440 | $1,751 | 32.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 123 | 450 | $8,100 | $1,332 | 16.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 16 | 60 | $3,300 | $753.28 | 22.8% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2022 | 17 | 710 | $53,250 | $562.99 | 1.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 20 | 44 | $1,848 | $477.95 | 25.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 25 | 1,108 | $1,108 | $106.95 | 9.7% |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | Office | 2022 | 12 | 400 | $16,400 | $105.49 | 0.6% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2022 | 17 | 66 | $264.00 | $45.34 | 17.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 46 | 93 | $15,066 | $9,546 | 63.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 73 | 154 | $17,710 | $8,892 | 50.2% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 16 | 75 | $26,625 | $8,425 | 31.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 61 | 97 | $10,088 | $6,318 | 62.6% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 52 | 52 | $7,800 | $4,267 | 54.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 35 | 35 | $9,275 | $4,236 | 45.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 26 | 26 | $5,850 | $2,849 | 48.7% |
About Dr. Hiral Parekh, MD
Dr. Hiral Parekh, MD is a Internal Medicine healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2008. The National Provider Identifier (NPI) number assigned to this provider is 1508026782.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hiral Parekh, MD has received a total of $3,340 in payments from pharmaceutical and medical device companies, with $637.22 received in 2024. These payments were reported across 139 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($2,081).
As a Medicare-enrolled provider, Parekh has provided services to 2,847 Medicare beneficiaries, totaling 32,419 services with total Medicare billing of $314,491. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Jacksonville, FL
- Active Since 06/11/2008
- Last Updated 09/23/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1508026782
Products in Payments
- IBRANCE (Drug) $138.01
- PROMACTA (Drug) $129.77
- FOUNDATIONONE (Device) $120.27
- IMBRUVICA (Drug) $112.35
- JAKAFI (Drug) $107.18
- DARZALEX (Biological) $101.09
- FEMARA (Drug) $83.76
- XOSPATA (Drug) $82.90
- XARELTO (Drug) $72.92
- LONSURF (Drug) $70.50
- KRAZATI (Drug) $66.59
- Lenvima (Drug) $63.72
- XTANDI (Drug) $63.04
- OXBRYTA (Drug) $59.43
- SCEMBLIX (Drug) $57.31
- KEYTRUDA (Biological) $56.91
- RYBREVANT (Drug) $47.40
- Vonjo (Drug) $40.58
- PIQRAY (Drug) $38.95
- INLYTA (Drug) $36.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Jacksonville
Siddharth Wayangankar, Md, MD
Internal Medicine — Payments: $1.3M
Internal Medicine $1.3M
Dr. Alan Miller, M.d, M.D
Internal Medicine — Payments: $770,575
Internal Medicine $770,575
Kalina Sanders, M.d, M.D
Internal Medicine — Payments: $626,907
Internal Medicine $626,907
Jose Soto Soto, Md, MD
Internal Medicine — Payments: $576,809
Internal Medicine $576,809
Dr. Jennifer Fulton, Md, MD
Internal Medicine — Payments: $556,016
Internal Medicine $556,016
Dr. Francis Farraye, M.d, M.D
Internal Medicine — Payments: $504,399
Internal Medicine $504,399